",,,hummm,,,is there any chance some of our oncology trial data will accompany these presentations??"

Probably too early to expect any meaningful data from the TNBC trial except for maybe an update on the dose escalation portion. "This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is dose escalation and Part 2 is a Simon 2-Stage design."

As for the mCRPC trial, we had better get an update!!!! We haven't heard anything since March 2019, 7 months ago. The mCRPC trial has an estimated completion data of October 2019!

BDAZ